The AERO Hybrid Tracheobronchial Stent System has been FDA cleared for treatment of malignant pulmonary obstructions, which is the blockage of the airway or tracheobronchial tree.
The major symptom of malignant pulmonary obstruction is difficulty in breathing, a condition that often requires hospitalization. The placement of a stent may improve the condition while reducing a patient's hospital stay. The AERO system expands Alveolus' domestic product range of next-generation nonvascular stents and stenting accessories.